Ischemia reperfusion injury
diseaseOn this page
Summary
Ischemia reperfusion injury (MONDO:0005203) is a disease and 83 clinical trials. Top therapeutic interventions include rosuvastatin, caffeine, and adenosine. A subtype of injury — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 83
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ischemia reperfusion injury |
| Mondo ID | MONDO:0005203 |
| EFO | EFO:0002687 |
| MeSH | D015427 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of injury. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: injury › ischemia reperfusion injury
Related subtypes (9): bone fracture, acute lung injury, spinal injury, radiation injury, burn, ankle injury, nervous system injury, frostbite, head injury
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 10 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Acetylcysteine | Phase 3 (in late-stage trials) |
| Basiliximab | Phase 3 (in late-stage trials) |
| Colchicine | Phase 3 (in late-stage trials) |
| Diltiazem | Phase 3 (in late-stage trials) |
| Fospropofol | Phase 3 (in late-stage trials) |
| Metformin | Phase 3 (in late-stage trials) |
| Nitric Oxide | Phase 3 (in late-stage trials) |
| Nitroglycerin | Phase 3 (in late-stage trials) |
| Propofol | Phase 3 (in late-stage trials) |
| Sevoflurane | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cyclosporine, Epoetin Beta, Epoprostenol, Etanercept, Glutathione, Heme Arginate, Infliximab, Melatonin, Nitrogen, Norethindrone, Reparixin, Sodium Chloride, Soybean Oil, Tacrolimus Anhydrous, Thrombin, Vitamin E.
Clinical trials & evidence
Clinical trials
Clinical trials: 83.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 43 |
| PHASE2 | 13 |
| PHASE4 | 11 |
| PHASE3 | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00430170 | PHASE4 | COMPLETED | Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? |
| NCT00441597 | PHASE4 | COMPLETED | Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo? |
| NCT00457405 | PHASE4 | COMPLETED | Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? |
| NCT00457652 | PHASE4 | COMPLETED | Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury? |
| NCT00609388 | PHASE4 | COMPLETED | Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation |
| NCT00987974 | PHASE4 | COMPLETED | Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury |
| NCT01610401 | PHASE4 | COMPLETED | The Metformin-FMD Trial |
| NCT02833688 | PHASE4 | COMPLETED | Effects of Dexmedetomidine on the Liver Injury After Hepatectomy |
| NCT03482544 | PHASE4 | COMPLETED | The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion |
| NCT04307290 | PHASE4 | COMPLETED | Dexmedetomidine on Tourniquet Induced -Systemic Effects |
| NCT05598177 | PHASE4 | COMPLETED | Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion Injury in Patients Undergoing Open Heart Surgery With Cardiopulmonary Bypass |
| NCT05430620 | PHASE3 | RECRUITING | Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys |
| NCT06582485 | PHASE2/PHASE3 | NOT_YET_RECRUITING | A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys |
| NCT00060450 | PHASE3 | TERMINATED | Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation |
| NCT01239563 | PHASE3 | UNKNOWN | Thymoglobulin Induction in Kidney Transplant Recipients |
| NCT01430156 | PHASE3 | COMPLETED | Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation |
| NCT01564095 | PHASE2/PHASE3 | TERMINATED | TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion |
| NCT05327348 | PHASE3 | UNKNOWN | Effectiveness of IV Vitamin C in Reducing Oxidative Stress Associated With Free Flap Surgery |
| NCT03663543 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Intravenous Estrogen in Kidney Transplant Study |
| NCT04005469 | PHASE1/PHASE2 | RECRUITING | Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation |
| NCT04750616 | PHASE2 | RECRUITING | NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial |
| NCT05004610 | PHASE2 | RECRUITING | Hypertonic Lactate After Cardiac Arrest |
| NCT07164833 | PHASE2 | RECRUITING | A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE) |
| NCT00224406 | PHASE2 | COMPLETED | Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation |
| NCT00248040 | PHASE2 | COMPLETED | Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation |
| NCT00405015 | PHASE2 | COMPLETED | The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. |
| NCT00876902 | PHASE2 | UNKNOWN | YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation |
| NCT01040013 | PHASE2 | COMPLETED | Gut Oxygenation and Laparoscopy |
| NCT01172171 | PHASE2 | COMPLETED | The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction |
| NCT01461512 | PHASE2 | UNKNOWN | Heme Arginate in Functional Magnetic Resonance Imaging (fMRI) |
| NCT01755858 | PHASE1/PHASE2 | TERMINATED | Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery |
| NCT04531579 | PHASE2 | WITHDRAWN | Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients |
| NCT04531592 | PHASE2 | WITHDRAWN | Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients |
| NCT05246618 | PHASE1/PHASE2 | COMPLETED | FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation |
| NCT06552442 | PHASE2 | COMPLETED | Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI |
| NCT01481974 | PHASE1 | COMPLETED | Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation |
| NCT04388761 | PHASE1 | WITHDRAWN | Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI) |
| NCT05215743 | PHASE1 | COMPLETED | Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study. |
| NCT06097702 | PHASE1 | COMPLETED | A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants |
| NCT06369350 | EARLY_PHASE1 | NOT_YET_RECRUITING | Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ROSUVASTATIN | 4 | 4 |
| CAFFEINE | 4 | 3 |
| ADENOSINE | 4 | 2 |
| ATORVASTATIN | 4 | 2 |
| DIPYRIDAMOLE | 4 | 2 |
| TACROLIMUS ANHYDROUS | 4 | 2 |
| TREPROSTINIL | 4 | 2 |
| URSODIOL | 4 | 2 |
| ACETYLCHOLINE | 4 | 1 |
| BASILIXIMAB | 4 | 1 |
| DIAZOXIDE | 4 | 1 |
| EPLERENONE | 4 | 1 |
| GLYBURIDE | 4 | 1 |
| NIACINAMIDE | 4 | 1 |
| OXYGEN | 4 | 1 |
| PREGABALIN | 4 | 1 |
| SODIUM CHLORIDE | 4 | 1 |
| SODIUM LACTATE | 4 | 1 |
| VALPROIC ACID | 4 | 1 |
| ESTROGEN | 3 | 1 |
| REPARIXIN | 3 | 1 |
| ELAMIPRETIDE HYDROCHLORIDE | 1 | 1 |
| CHEMBL4587343 | 0 | 2 |
| CHEMBL1357356 | 0 | 2 |
| CHEMBL606298 | 0 | 2 |
| CHEMBL4564923 | 0 | 1 |
| CHEMBL5409583 | 0 | 1 |
| PARAXANTHINE | 0 | 1 |